Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Mannkind Corp (NQ: MNKD )

5.850 +0.050 (+0.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,961,510
Open 5.890
Bid (Size) 5.850 (10)
Ask (Size) 5.950 (1)
Prev. Close 5.800
Today's Range 5.690 - 5.895
52wk Range 3.170 - 6.040
Shares Outstanding 264,305,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
Our first-ever twin bill. 
Via The Motley Fool
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire

Performance

YTD
+49.23%
+49.23%
1 Month
+11.64%
+11.64%
3 Month
+39.95%
+39.95%
6 Month
+70.06%
+70.06%
1 Year
+32.65%
+32.65%

More News

Read More
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
Earnings Scheduled For February 27, 2024
Via Benzinga
MannKind Earnings Preview
Via Benzinga
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
From MannKind
Via GlobeNewswire
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
MannKind Repays Certain Debt Obligations
From MannKind
Via GlobeNewswire
MannKind Announces CFO Transition
From MannKind
Via GlobeNewswire
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Exposures Product Safety
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With MannKind Stock?
Via Benzinga
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
From MannKind
Via GlobeNewswire
Cramer Says Sprout Social Is In A 'Hot Spot,' But This Energy Stock Is 'Too Down And Out'
Via Benzinga
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
From MannKind
Via GlobeNewswire
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
From MannKind
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.